☆ 4.7 Review

Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review

JOURNAL OF MEDICAL VIROLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

TOTAL ANTI-SARS-COV-2 ANTIBODIES MEASURED 6 MONTHS AFTER PFIZER-BIONTECH COVID-19 VACCINATION IN HEALTHCARE WORKERS

Gian Luca Salvagno et al.

Summary: After healthcare workers received two doses of the Pfizer-BioNTech COVID-19 vaccine, serum levels of total anti-SARS-CoV-2 antibodies peaked 1 month after the second dose and gradually declined at 3 and 6 months. Despite the decline, antibody levels remained higher than the cut-off point, with no cases of seronegativization after 6 months. Baseline seropositive individuals experienced a more significant decline in antibodies, and younger subjects and women had consistently higher antibody levels at the 6-month follow-up.

JOURNAL OF MEDICAL BIOCHEMISTRY (2022)

Add to Collection

Review Microbiology

A Review on the Effectivity of the Current COVID-19 Drugs and Vaccines: Are They Really Working Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants?

Rashed Noor

Summary: Scientists have been working hard to design effective drugs and vaccines against SARS-CoV-2 to eradicate the COVID-19 pandemic. While some drugs and vaccines have shown effectiveness, the emergence of new virus variants and increased cases have raised doubts about their usefulness. Current reviews have evaluated the efficacy of different drugs and vaccines and recommended measures for future remedies.

CURRENT CLINICAL MICROBIOLOGY REPORTS (2021)

Add to Collection

Article Medical Laboratory Technology

IgG antibodies against SARS-CoV-2 decay but persist 4 months after vaccination in a cohort of healthcare workers

Giulia Brisotto et al.

Summary: The study showed that SARS-CoV-2 mRNA vaccines can induce a lasting IgG response for at least 4 months, even beyond the parameters of clinical trials. The observed antibody decay at follow-up suggests further research is needed to characterize the immune response and identify individuals with low anti-SARS-CoV-2 immunity who may require a vaccination booster.

CLINICA CHIMICA ACTA (2021)

Add to Collection

Letter Public, Environmental & Occupational Health

Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months

Domenico Ponticelli et al.

JOURNAL OF TRAVEL MEDICINE (2021)

Add to Collection

Letter Urology & Nephrology

Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost

Tamara Davidovic et al.

KIDNEY INTERNATIONAL (2021)

Add to Collection

Article Infectious Diseases

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021

Kamal Abu Jabal et al.

Summary: An analysis of 514 Israeli healthcare workers showed that the BNT162b2 mRNA COVID-19 vaccine had similar immunogenicity by ethnicity and sex, but decreased with age. Individuals with prior COVID-19 infection had significantly higher antibody titres compared to those who were naive, regardless of pre-vaccination IgG levels.

EUROSURVEILLANCE (2021)

Add to Collection

Article Immunology

COVID-19 vaccine-Long term immune decline and breakthrough infections

Johad Khoury et al.

Summary: The antibody levels decline rapidly one month after the second dose of the vaccine, with the average antibody level four months after vaccination being only 6% of the peak levels. During the study period, there were 4 breakthrough infections, all of which were mild or asymptomatic, with a sharp elevation in antibody levels seen after infection.

VACCINE (2021)

Add to Collection

Article Immunology

Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine

Annalisa Ciabattini et al.

Summary: The study found that spike-specific antibodies and memory B cells still persisted up to 6 months after BNT162b2 vaccine administration, indicating a lasting immune protection against SARS-CoV-2 virus.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Public, Environmental & Occupational Health

The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021

Sarah Mbaeyi et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Review Biochemistry & Molecular Biology

COVID-19 mRNA vaccines

Qinrui Huang et al.

Summary: The ongoing COVID-19 pandemic has accelerated the development of mRNA vaccines, with positive results reported and future challenges ahead.

JOURNAL OF GENETICS AND GENOMICS (2021)

Add to Collection

Article Immunology

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers

Jean-Louis Bayart et al.

Summary: Data from this study showed a significant decline in antibodies levels at day 180 post SARS-CoV-2 vaccination, with a more pronounced decrease in neutralizing antibodies. The estimated half-life of IgG was around 21 days in seronegative individuals and 53 days in seropositive individuals, while the half-life of total antibodies ranged from 68 to 114 days. The decline in neutralizing antibodies was particularly stark, with around 45% of subjects testing negative at day 180.

VACCINES (2021)

Add to Collection

Article Immunology

Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers

Flaminia Campo et al.

Summary: The study indicates that the BNT162b2 vaccine shows antibody persistence at 6 months after the first dose, with a certain decline. Age, gender, and previous COVID-19 infection have an impact on immune response levels.

VACCINES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

COMPARISON OF FIVE COMMERCIAL ANTI-SARS-COV-2 TOTAL ANTIBODIES AND IgG IMMUNOASSAYS AFTER VACCINATION WITH BNT162B2 MRNA

Elisa Danese et al.

Summary: The study compared data of five commercial anti-SARS-CoV-2 immunoassays after administration of an mRNA vaccine, demonstrating that all evaluated immunoassays are suitable for monitoring anti-SARS-CoV-2 neutralizing antibodies response in subjects undergoing mRNA COVID-19 vaccination.

JOURNAL OF MEDICAL BIOCHEMISTRY (2021)

Add to Collection

Article Virology

Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection

Annapaola Callegaro et al.

Summary: A single mRNA vaccine dose seems sufficient to provide immunity in individuals with previous SARS-CoV-2 infection, showing similar results to a full vaccine schedule. Adverse events after vaccination were more common after the second dose, with higher frequency in exposed individuals compared to naive ones.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Geriatrics & Gerontology

Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study

Sergio Salmeron Rios et al.

Summary: In a longitudinal cohort study in long-term care facilities in Albacete, Spain, 134 older adults aged >= 65 years received two doses of the BNT162b2 mRNA COVID-19 vaccine, with antibody levels measured 21.9 days after each dose. The vaccine was found to be safe and produced immunogenicity in older adults, regardless of their frailty and disability profiles. Residents with prior COVID-19 infection showed increased antibody levels post-vaccination.

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Joseph E. Ebinger et al.

Summary: Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Nicole Doria-Rose et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination

Gian Luca Salvagno et al.

Summary: This study found significant differences in post-mRNA COVID-19 vaccine immune response between baseline seronegative and seropositive subjects, with the latter's immune response appearing to depend on age and sex, while the former's immune response appears to be dependent on baseline anti-SARS-CoV-2 antibodies levels.

DIAGNOSTICS (2021)

Add to Collection

Article Medicine, General & Internal

Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals

Elizabeth Fraley et al.

Summary: This study characterized humoral immune responses during vaccination with the BNT162b2 vaccine in individuals with or without prior history of natural SARS-CoV-2 infection, demonstrating differences in antibody levels and epitope specificity between the two groups. The findings support the consideration of prior infection history as a guide for future vaccination strategies and provide valuable insights for vaccine development.

BMC MEDICINE (2021)

Add to Collection

Editorial Material Microbiology

Global COVID-19 vaccine inequity: The scope, the impact, and the challenges

Archana Asundi et al.

Summary: Global vaccine inequity is prolonging the COVID-19 pandemic. Challenges in vaccine development, manufacturing, and distribution need to be addressed to resolve this crisis.

CELL HOST & MICROBE (2021)

Add to Collection

Article Medical Laboratory Technology

Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers

Andrea Padoan et al.

Summary: The study found significant differences in antibody levels at day 12 after receiving the BNT162b2 vaccine between infection-naive individuals and those with previous natural infection, but no differences were observed thereafter. There were no statistically significant differences between males and females, while individuals over 60 years of age had lower antibody levels at day 12 but not at day 28. The influence of sex and age on vaccine responses warrants further investigation, with age showing particular significance.

CLINICA CHIMICA ACTA (2021)

Add to Collection

Editorial Material Medical Laboratory Technology

Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role?

Giuseppe Lippi et al.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Madhumita Shrotri et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Yinon M. Bar-On et al.

Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Moriah Bergwerk et al.

Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19 booster vaccines: What we know and who's doing what

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Immunology

Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart

Alberto Modenese et al.

Summary: A study conducted on healthcare workers at a nursing home in Northern Italy showed that all workers had high antibody titers after receiving two doses of the BNT162b2 vaccine, even when administered four weeks apart. Adverse effects were more common after the second dose, but there were no severe adverse effects observed.

VACCINES (2021)

Add to Collection

Article Medicine, General & Internal

Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?

Giuseppe Lippi et al.

Summary: Although testing for anti-SARS-CoV-2 antibodies in recipients of COVID-19 vaccination can provide benefits such as assessing baseline seroprevalence, identifying non-responders, and detecting antibody decay, challenges like unclear equivalence between antibody titer, neutralizing activity, and vaccine efficiency; lack of cost-effective analyses; and increased laboratory workload remain. A potential solution involves prioritizing testing for high-risk individuals and those with lower vaccine immunogenicity.

DIAGNOSTICS (2021)

Add to Collection

Article Health Care Sciences & Services

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

Paul Naaber et al.

Summary: The study found that antibody levels declined at 12 weeks and 6 months after receiving two doses of BNT162b2 vaccine, with Spike antibody levels at 6 months being similar to those in individuals who received one dose or had recovered from COVID-19. Most individuals developed Spike-specific memory T cell responses, which were lower in those with higher T cell immunosenescence. Antibody response was negatively correlated with age and positively correlated with the total score of vaccination side effects.

LANCET REGIONAL HEALTH-EUROPE (2021)

Add to Collection

Article Medicine, General & Internal

Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine

Raul Pellini et al.

Summary: The study found that 99.5% of healthcare workers developed a humoral immune response after vaccination, with female and young participants showing an increased capacity for humoral immune responses. Body mass index and hypertension seem to have no association with the differences in immune response to the vaccine.

ECLINICALMEDICINE (2021)

Add to Collection

Review Medical Laboratory Technology

The COVID-19 pandemic

Marco Ciotti et al.

CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2020)

Add to Collection

Article Environmental Sciences

Spread of SARS-CoV-2 through Latin America and the Caribbean region: A look from its economic conditions, climate and air pollution indicators

Tomas R. Bolano-Ortiz et al.

ENVIRONMENTAL RESEARCH (2020)

Add to Collection

Article Multidisciplinary Sciences

Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission

Hannah Peckham et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Letter Immunology

Patterns of IgG and IgM antibody response in COVID-19 patients

Xuemei Liu et al.

EMERGING MICROBES & INFECTIONS (2020)

Add to Collection

Review Physiology

The evolution of greater humoral immunity in females than males: implications for vaccine efficacy

Ashley L. Fink et al.

CURRENT OPINION IN PHYSIOLOGY (2018)

Add to Collection

Review Cell Biology

Age effects on B cells and humoral immunity in humans

Daniela Frasca et al.

AGEING RESEARCH REVIEWS (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.